Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...
Johnson & Johnson (NYSE:JNJ) is advancing psychedelic medicine with Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression and acute suicidal ideation. Since its ...
A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.
J&J is already seeing strong sales growth for its treatment-resistant depression (TRD) and MDD therapy Spravato (esketamine), ...
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...
Johnson & Johnson (NYSE:JNJ) is advancing psychedelic medicine with Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression and acute suicidal ideation. Since its ...
Johnson & Johnson's Spravato therapy for treatment ... the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from ...
Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results